# **1 Population Pharmacokinetics of Oxcarbazepine: A Systematic Review**

- 2 Yue-ting Chen<sup>1, 2#</sup>; Chen-yu Wang<sup>1#</sup>; Yi-wei Yin<sup>1#</sup>; Zi-ran Li<sup>3</sup>; Wei-wei Lin<sup>4</sup>; Min
- 3 Zhu <sup>1,2</sup>; Zheng Jiao <sup>1\*</sup>
- <sup>4</sup> <sup>1</sup> Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University,
- 5 Shanghai, China;
- <sup>2</sup>School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University,
- 7 Nanjing, China;
- <sup>3</sup>Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China;
- <sup>4</sup>Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University,
- 10 Fuzhou, China.
- 11 Yue-ting Chen, Chen-yu Wang and Yi-wei Yin contributed equally to this work.
- 12 \*Corresponding author:
- 13 Zheng Jiao, Professor
- 14 Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University
- 15 241 Huaihai West Road, Shanghai, China, 200030
- 16 Tel.: +86 (21) 2220 0000 ext 3021
- 17 E-mail: jiaozhen@online.sh.cn;
- 18 ORCID: Zheng Jiao: https://orcid.org/0000-0001-7999-7162
- 19
- 20

# 21 Abstract

Introduction: Oxcarbazepine is commonly used as a first-line drug in the treatment
of partial seizures. Due to the high pharmacokinetic variability of oxcarbazepine,
many population pharmacokinetic models have been developed to optimise the
dosing regimen of oxcarbazepine.
Areas covered: This review summarize the published population pharmacokinetic
studies of oxcarbazepine in children and adults. The quality of the identified reports

28 from the PubMed and Embase databases was also evaluated. We also explored the

- 29 significant covariates that may have an impact on the dosage regimen and clinical use
- 30 of oxcarbazepine.

Expert Opinion: The oxcarbazepine dose regimen was dependent on weight and co-administration with enzyme-inducing medications. In order to achieve more accurate treatment, we should establish PK / PD model of OXC to evaluate the effectiveness of dose adjustment from pharmacodynamic indicators. Furthermore, exploring the pharmacokinetic in specifical patients, such as infants is essential to improve its safety.

37 Keywords: Epilepsy; Nonlinear mixed effect modelling; Oxcarbazepine; Population
38 pharmacokinetic;

2

# 39 Article highlights

40	•	In this review, we identified weight, renal function, and co-administered
41		medications as covariates that most likely to influence oxcarbazepine
42		pharmacokinetics.
43	•	Comparing to adult patients, paediatric patients show a higher clearance per
44		kilogramme weigh which lead to higher doses per kilogramme; they may also
45		require therapeutic drug monitoring owing to a larger variation in clearance.
46	٠	Further studies are essential to evaluate oxcarbazepine pharmacokinetics in
47		special populations such as infants.

## 48 **1. Introduction**

Oxcarbazepine (OXC) is a commonly used anti-epilepsy drug with a chemical structure similar carbamazepine (CBZ) [1]. It was approved by the Food and Drug Administration as a monotherapy and adjunctive therapy for partial seizures in adult and paediatric patients. It prevents seizures mainly through the blockage of voltage-dependent sodium channels, similar to CBZ [2]. Owing to its comparable effectiveness but better safety and tolerability, OXC is usually used as an alternative to CBZ in patients who are unable to tolerate CBZ [3,4].

56 Oxcarbazepine is completely absorbed (>95%) and quickly transformed to its 57 active metabolite 10-hydroxycarbazepine (MHD) by cytosolic enzymes after oral 58 administration [5,6]. Owing to its rapid metabolism, OXC has a much lower area under the concentration-time curve (AUC) than MHD in vivo (16.05 vs. 215.52 59 60 µg·h/ml) [7]. Thus, the effectiveness of OXC is mainly determined by measuring 61 MHD concentration [8]. Following OXC administration, the concentration of MHD 62 reaches a peak in approximately 2-4 h [9]. MHD has a low protein binding rate 63  $(\sim 39\%)$  [10], and its volume of distribution (Vd) is between 0.3 and 0.8 L/kg [6]. MHD is excreted unchanged in the urine or eliminated in conjugation with uridine 64 65 diphosphate-glucuronosyltransferase (UGT), with only a small fraction (4%) being 66 oxidised to its dihydroxy derivative (DHD) [5,11].

In special patient populations, such as patients with renal insufficiency, patients
who are co-administered OXC with enzyme-inducing antiepileptic drugs (EIAEDs) as
well as the elderly and infants, the pharmacokinetics (PK) of MHD varies greatly [12].

70	Rouan et al. [12] reported that the mean $AUC_{0-168 h}$ of MHD in patients with severe
71	renal impairment was around 2-2.5 times higher than that in healthy subjects after
72	receiving a single oral dose of OXC. A high exposure to OXC is associated with an
73	increased incidence of side effects [13]; therefore, to ensure effectiveness and safety,
74	therapeutic drug monitoring (TDM) is essential for patient-specific dose adjustment
75	[14]. Ideally, individualised doses need to be developed at the beginning of treatment;
76	however, the current TDM approach is usually implemented during the course of the
77	treatment. The population pharmacokinetic (PPK) approach has been used to identify
78	significant covariates that influence PK and is often used in clinical practice through
79	Bayesian forecasting to develop individualised therapy at the beginning and even
80	during the course of treatment [15,16].
81	Despite the reports of PPK study are numerous, no research has been conducted to
82	review the PPK of MHD. Analysing and understanding the significant covariates and
83	their relationship in different patient populations is critical for the development of
84	appropriate regimens for individualised therapy. In this review, we aim to summarise
85	the significant covariates affecting PK, identify unexplored covariates, and provide
86	evidence for the model informed of OXC.

87 2. Methods

#### 88 2.1 Search Strategy

The PubMed and Embase databases were used to systematically search for articles on PPK of OXC published before 31 October 2020 followed the principles of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)

92	statement. The search terms used included "oxcarbazepine", "oxcarbamazepine",
93	"ocbz", "oxtellar", or "trileptal" and "population pharmacokinetic", "pharmacokinetic
94	modeling", "nonlinear mixed effect model", "NONMEM", "Pmetrics",
95	"WINNONMIX", "ADAPT", "P-PHARM", "nlmixed", "NLME", "USC*PACK", or
96	"MONOLIX". Besides, references of all included studies were searched.

97 All the relevant articles selected from the databases and reference lists were 98 screened to evaluate their eligibility for inclusion according to the following criteria: 99 target group of studies was human; OXC was the study drug; PPK analysis was 100 conducted in the study; and the study was published in English. A study was excluded 101 if it was a review or external evaluation article; the data presented overlapped with 102 previous studies but with smaller sample sizes; or the PK parameters were incomplete. 103 Two independent authors screened the title and abstracts as well as the full-text of 104 each article to determine their eligibility. Discrepancies were resolved by a third 105 senior investigator.

106 **2.2 Evaluation of Literature Quality** 

The quality of the PPK report was evaluated according to previous guidelines of PK reports (Kanji et al. [17] and Jamsen et al. [18]) that assist in transparent and complete reporting. A checklist with 24 items was developed to summarise the key points of the report. All items were categorised into five sections: the title and abstract, background and introduction, methods, results, and discussion and conclusion, according to their relevance to the sections of the research report.

113 If there was a description in the paper that conforms to the criterion, the scoring

item will be counted as 1 point. If it was not reported, zero points were given. Each
identified study was evaluated based on these criteria. Compliance of the included
PPK studies was reported as a proportion. The compliance rate was calculated as
follows:

compliance rate (%) = 
$$\frac{sum of reported items}{sum of all items} \times 100\%$$

# 118 2.3 Data Extraction

A standardised data collection was used to extract the relevant information from each eligible study as follows: patient characteristics, such as age, weight, and laboratory test, ; the study design, such as research types, quantity of subjects and observations; dose regimens; OXC formulation; and PPK study information such as data analysis software and algorithm, model strategies, final PK parameters, and tested and significant covariates.

#### 125 2.4 Study Comparison

We developed virtual patients with different age: infants (10 kg, 1-year-old) taking 300 mg OXC every 12 h (q12h), children (30 kg, 10 years old) taking 300 mg OXC q12h, and adults (70 kg, 40 years old) taking 600 mg OXC q12h. The concentration–time profiles in virtual patients were drew on the basis of the restored PPK model and study population in each included study. They received multiple doses of OXC alone and achieve stable state. The sex of the virtual patient was selected as male.

133 The identified covariates effect on clearance (CL) in the included studies was134 analysed and showed by a forest map. The CL change less than between 80%-125%

135	was not considered to have a significant clinical correlation [19]. For binary
136	covariates such as co-administration with medications, we use 0 for monotherapy and
137	1 for co-administration with medications. For continuous covariates that were
138	included in only one model, we used the same range values as the study. For
139	continuous covariates included in multiple studies, we scaled them to the same range
140	for comparison. The effect of each covariate on CL was shown as the ratio of CL in
141	the range of the covariate divided by the typical CL value in each study.
142	The simulation was conducted using NONMEM (version 7.4; ICON Development
143	Solutions, Ellicott City, MD, USA) software. R (version 3.5.1;
144	http://www.r-project.org/) was used to generate the concentration-time plots and

145 forest plots.

146 **3. Results** 

#### 147 **3.1 Study Identification**

A total of 155 articles were selected: 87 articles were selected from PubMed; 67 articles from the Embase database; and one article from the references of selected articles. After initial screening, 16 full-text studies were assessed for eligibility. One study was excluded because the final PK parameters were not presented [20], and two were excluded because of language [21,22]. In addition, the study conducted by Sallas et al. [23] was excluded because the study data overlapped with that of Sugiyama et al. [24]. Finally, 12 articles were included in the study (**Fig. 1**).

# 155 **3.2 Evaluation of Literature Quality**

156 According to the guidelines, we summarised the quality of OXC PPK studies based

157	on 35 items, as outlined in Table 1. Compared with that of the PPK articles published
158	between 2005 and 2013, the quality of PPK studies published between 2014 and 2019
159	significantly improved [compliance rate median (range): 71.4% (68.6%-71.4%) vs.
160	94.3% (85.7%–97.1%)]. Generally, prospective studies show better compliance than
161	retrospective studies; however, the prospective study by Northam et al. [25] had a
162	compliance rate of only 73.5%. This may be due to the lack of a standard reporting
163	guide published at that time.

After the guidelines were published, the quality of PPK study reports improved over time. Nonetheless, several studies still have compliance rate of less than 60%, which included deficiencies in the description of sample, statistical methods and software, and methods for handling missing data.

#### 168 **3.3 Study Characteristics**

169 The included studies were published from 2005 to 2019. The total quantity of 170 subjects in included articles between 12 and 573. Most PPK analysis was performed 171 in patients with epilepsy [24,26-33], and only Antunes et al. [34] enrolled healthy 172 subjects. One study was conducted only in infants [25], seven studies were conducted 173 in children [24,25,27,28,30-32], two studies included both children and adults [26,33], 174 and two studies only enrolled adults [29,34]. Subjects in all the included studies were 175 administered OXC orally, with doses ranging from 75 to 1800 mg/d. In most studies, 176 sparse sampling was employed, with 1 to 4 samples collected per individual. Detailed 177 characteristics of all included studies were listed in Table 1.

178 The PPK analyses were all conducted using population modelling software,

179 including NONMEM (Icon, Dublin, Ireland) [24-26,29-31,34,35], Phoenix NLME 180 (Certara L.P. Pharsight, St. Louis, MO, USA) [26–28], and Monolix (Lixoft, Antony, 181 France) [32]. The most commonly used algorithm was first-order conditional 182 estimation with the  $\eta$ - $\varepsilon$  interaction. 183 Most studies described the PK of MHD as a one-compartment model with 184 first-order absorption and elimination. Rodrigues et al. [32] described the PK of OXC 185 and its active metabolite MHD with a two-compartment model with first-order 186 absorption and elimination. Antunes et al. [34] described the PK of OXC and its 187 active metabolite enantiomers using a two-compartment model with transit absorption 188 and first-order elimination. 189 All studies used either internal or external evaluation. The commonly method of 190 external evaluation is the goodness-of-fit plot, while the second popular method was

the visual predictive check. Although a normalised prediction distribution error
(NPDE) has better properties [36], it is not commonly used [29,30,32,34]. Four
studies performed an external evaluation using an independent dataset, all of which
showed acceptable predictability [28,30,31,33].

## 195 **3.4 Study Comparison**

There were no obvious differences in the PK of OXC due to ethnicity. **Fig. 2** shows concentration-time profiles of all studies that are simulated with virtual infant (a), children (b) and adult (c) patients. The model established by Peng et al. [27] which presented lower CL, displayed a much higher trough concentration ( $C_{trough}$ ) than others (CL: 0.016 vs. 0.035–0.073 L/h/kg). On the contrary, the PPK model

201	established by	Yu et al.	[33] which	presented a higher	CL.	showed a	considerably
-----	----------------	-----------	------------	--------------------	-----	----------	--------------

lower C<sub>trough</sub> than others (CL: 0.084 vs. 0.035-0.073 L/h/kg).

203	The estimated median CL was 0.078 L/h/kg for infants (10 kg, 1 year) [25], 0.058
204	(range: 0.016-0.084) L/h/kg for children (30 kg, 10 years) [24,26-28,30-33], and
205	0.033 (range: 0.029-0.0599) L/h/kg for adults (70 kg, 40 years) [26,29,33-35]. The
206	median CL per kg in infants and children was higher than that in adults. Furthermore,
207	children had a larger variability in CL than adults (0.016-0.084 L/h/kg vs. 0.029-0.06
208	L/h/kg).

- 209 Moreover, the median Vd per kg in infants and children was higher than that in
- adults. The determined median Vd was 1.38 L/kg for infants, 0.78 (range: 0.47–2.16)
- L/kg for children, and 0.45 (range: 0.2–1.48) L/kg for adults.

The final PK parameters included in our review are summarised in **Table 3**. The between-subject variability (BSV) was determined from exponential models in all included studies. The median (range) BSV was as follows: CL, 16.84% (11.09%–34.21%); Vd, 35.35% (6.88%–104.4%); and Ka, 24.05% (8.27%–39.82%). The residual unexplained variability (RUV) was described using the proportional model: 12.05% (4%–32%) or additive model: 3.396 mg/L (0.93–0.512 mg/L).

All PPK analysis intended to explain the BSV of MHD PK by investigating possible covariates. The covariates investigated and identified in each study are visually shown in **Fig. 3**. The commonly investigated covariates included weight, sex, age, co-administered medications, body surface area, and estimated glomerular filtration rate (eGFR). The identified covariates for CL included weight,

co-administered medications, eGFR, dose. All the investigated and identifiedcovariates in the PPK model are summarised in Table S1.

It was found that eGFR significantly affected MHD CL, according to the observations from Lin et al. [29]. In patients with impaired renal function (eGFR: 20–80 mL/min), the CL was 34.8% (9.4%–64.2%) lower than those with normal renal function.

There was one study identified dose could affect CL, which may indicate a nonlinear elimination of MHD [27]. However, these effects may on account of the dose adjustment in clinical practice according to the TDM process, which can be misinterpreted as nonlinearity in the system [37]. Therefore, further in-depth study on the possible PK of MHD is necessary.

The influence of all included covariates on CL is shown in **Fig. 4**. The ranges of continuous covariates that were scaled are as follows: the weight of adults was set at 40–100 kg and that of children was set at 16–40 kg. The age was set as 18–75 years. The range of eGFR and alanine aminotransferase (ALT) were set as 20–120 mL/min and 5–150 U/L, respectively. The dose of OXC was set as 75–1350 mg/kg/d.

Ten of all studies that investigated impact of the weight indicated that it was associated with the CL of MHD [24,26-32,34,35]. Weight had a significant influence on CL. Our finding showed that the CL of patients with different weight could range from 0.54 to 1.8 times compared to the typical patient (children: 30kg, adults: 70kg). Co-administration with EIAEDs also significantly affected CL in children and adults, which approximately increased 1.17 to 1.63 times [24-26,28,32]; in four studies, the

245	clinical significance of the impact of EIAED co-administration on CL was more than
246	20% [24-26,32]. eGFR was identified to significantly affect the CL of adults with a
247	range of 0.33 to 1.24 times [29] compared to a typical patient with an eGFR of 90
248	mL/min. ALT was also found to have a significant impact on CL in children, with a
249	range of 0.73 to 1.35 times compared to a typical patient with an ALT level of 30 U/L $$
250	[33].

251 Four studies conducted a model-based simulation to show the influence of 252 covariates on the PK profile and optimize the dosage regimen to achieve the target 253 MHD concentrations of 3 and 35 mg/L recommended by the current guideline [29-32]. 254 For adults and paediatric patients, all the four studies recommended adjusting the 255 dosage [29-32]. Chen et al. [31] and Rodrigues et al. [32] had a similar recommended 256 dose range for paediatric patients based on their weight. However, Lin et al. [30] 257 recommended a lower dose than others, which may be explained by the lower CL in 258 their study than others (0.04 L/h/kg vs. 0.059/0.057 L/h/kg). Meanwhile, Rodrigues et 259 al. [32] also recommended increasing the maintenance dose by 50% above the 260 recommended maintenance dose for children treated with EIAEDs.

261 4. Discussion

To our knowledge, this is the first review that summarised data concerning previously published PPK models of OXC and its active metabolite MHD. We found considerable PK differences between children and adults. We also provided evidence regarding adjustment of the dose regimen according to weight, co-administration with EIAEDs, and eGFR.

267	The PK of MHD showed no significant differences due to ethnicity. According to
268	the PPK studies, there were similar PK profiles in adults. The weight-standardised CL
269	in Caucasians (median: 0.045, range: 0.029-0.060 L/h/kg) was similar to that in
270	Asians (median: 0.036, range: 0.033–0.039 L/h/kg) (P > 0.05). Likewise, most PPK
271	studies performed in paediatric patients also displayed comparable PK profiles.
272	Moreover, Sugiyama et al. [24] directly compared the PK of MHD among Caucasian,
273	Black, and Asian populations and found no obvious differences among these
274	sub-populations. Nevertheless, studies conducted in Chinese populations showed
275	larger variabilities than other ethnicities (0.016-0.084 L/h/kg vs. 0.043-0.078 L/h/kg).
276	The reason for this is unclear and may require still exploration.

277 The PK of MHD displayed considerable difference among infant, children, and 278 adult patients. Adults generally displayed lower CL per kg than the infants and 279 children, consistent with the classical PK investigations [38]. This difference may be 280 attributed to the lower body fat/lean mass ratio, higher kidney blood flow, and higher 281 total body water in children [39]. Furthermore, children had a wider 282 weight-standardised CL range than adults, which is attributed to the maturity of the 283 liver and inefficient UGT enzyme capacity [40,41]. A higher CL resulted in a lower 284 concentration of MHD. Therefore, a higher dosage could be used in paediatric 285 patients to achieve the target steady-state concentration of MHD [23].

Recently, OXC was increasingly off-label used to treat epileptic seizures in infants [39] owing to its linear PK, better safety, and well-tolerated profile [6]. Piña-Garza et al. [42] reported that OXC is relatively safe and effective in the treatment of infant

seizures. To date, only one PPK study has been conducted in paediatric patients aged
0.2 to 3.75 years [25]; therefore, clinical data of OXC in the treatment of infants are
limited. To ensure better efficacy and safety in infants, further studies are necessary to
explore the covariates that affect the variability of OXC.

293 Previous PPK studies found that EIAEDs could significantly increase the CL of 294 MHD. This is consistent with the PK study performed by McKee et al. [43], who 295 found that CBZ and phenytoin (PHT) decreased the AUC of MHD by 40% and 29%, 296 respectively. As MHD is primarily cleared via glucuronic acid conjugation, EIAEDs 297 may play a more important role through the induction of UGT-mediated 298 glucuronidation to decrease serum MHD concentration [35]. Lower exposure could 299 increase the risk of seizures [44]; therefore, the dose of OXC may be increased when 300 co-administered with EIAEDs.

301 Renal function may also influence the CL of MHD because OXC and MHD are 302 almost completely excreted by the kidney (94%–97.7%) [5]. Lin et al. [29] found that 303 MHD CL decreased by 64.2% when the eGFR decreased to 20 mL/min and 304 recommended dose adjustment according to eGFR in adult patients. When the eGFR 305 is normal, at approximately 90–120 mL/min, the recommended dose is 225 or 300 mg 306 q12h [29].When the eGFR is less than 30 mL/min, the recommended dose is 75 mg 307 q12h. This was similar to the OXC label recommendation that indicated that patients 308 with impaired renal function (creatinine clearance <30 mL/min) should initiate OXC 309 at one-half of the dose of 300 mg/day q12h. Therefore, to ensure a safe dose for adults 310 with renal dysfunction, a more detailed dose recommendation may be required.

311 However, there are also PPK studies that did not identify eGFR as a covariate [24,33]. 312 This may be because of the low proportion of study cohorts with low eGFR levels. 313 Thus, patients with renal impairment on MHD clearance warrant further investigation 314 to optimise their dosing regimen. 315 There were many unknown variabilities in children that could not be explained by 316 previously reported PPK models. In the included studies, children had a larger RUV 317 (additive model 0.93–5.12 mg/L; proportional model 4%–32%) than adults (RUV: 318 additive model 2.38–3.80 mg/L; proportional model 1.7%–24.5%). Moreover, the 319 practice guideline for the TDM of AEDs indicated the benefits of TDM for children 320 such as diagnosis of clinical toxicity and guide dosage adjustment [45]. Thus, TDM 321 monitoring is more crucial for paediatric patients taking OXC.

#### 322 **5.** Conclusions

The PPK studies of OXC have been extensively reviewed. The PK of MHD has a large difference between children and adults. Furthermore, children have a larger variability in PK than adults. This review showed that to optimise the dosing regimen of OXC, the weight, identity of co-administered drugs, and renal function of patients should be considered.

#### 328 6. Expert Opinion

Long-term maintenance therapy with drugs is one of the important ways of anti-epilepsy. It is high requirements for maintenance dose and dose adjustment, and most antiepileptic drugs have great variability. Therefore, in order to improve the safety and effectiveness, researchers have conducted PPK studies on antiepileptic

333 drugs, hoping to find the potential covariates that affect its PK variation.

334	Although, there are many PPK models established, few articles summarised the
335	information of the published PPK studies. This review attempts to summarize the
336	knowledge concerning the PPK modeling of oxcarbazepine to determine the factors
337	that can affect its clearance in the body. We find that there are no significantly
338	difference on races. However, our research shows that children have more variation
339	than adults. Finally, we also explored the significant covariates that may have clinical
340	impact to provide evidence for adjusting dosage regimens of oxcarbazepine.

341 Owing to the better PK profile and formula diversity, it is increasingly used in 342 the special populations, such as infants and elders. Infants have great variability 343 because of their physiological characteristics and TDM may help to optimize the 344 dosage regimen. However, most hospitals do not realize the importance of TDM 345 monitoring. In the future five years, it is necessary to conduct further studies on 346 infants to find significant covariates that affects their PK variation. Nevertheless, the 347 covariates selected are often different from the theory. This may be due to the smaller 348 variation range of the covariates or the lower proportion of the covariates with large 349 variation range. Therefore, in the future PPK studies, we need to focus on the 350 collection of people with large variation of potential covariates suspected in clinical 351 practice. We maybe get objective and credible results.

In clinical practice, we need to optimize dosing according to PK/PD. PPK studies had shown that the co-administration with inducers can increase the dose of OXC to achieve the therapeutic target concentration. However, there is no corresponding PD

index to determine whether the dose of OXC should be increased in combination with inducers. Therefore, it is very important to establish PK / PD model to explore the relationship between dose-exposure-response. Furthermore, we can also use the established PK / PD model to refine the treatment window in the different disease severity and population.

# 360 6.1 Five-year Review

In order to optimize the clinical administration scheme and reduce the occurrence of adverse events, PPK modeling was conducted for drugs with large variability and narrow treatment window. Although many models have been established, there is no unified standard for the quality of effective identification models. External validation is the most. In the five future years, it will explore the criteria for evaluating the quality of models and apply them to evaluate the quality of published models.

367 The ultimate purpose of establishing PPK model is to solve practical difficulties. 368 However, the application of PPK models is mainly based on dose simulation. In the 369 future, exploring meaningful clinical application is one of the main development 370 directions of PPK study. For instance, the PPK model is used for the remedial 371 administration of missed late administration. Epilepsy patients are stricter with the 372 time of taking drugs. Once the occurrence of missing a dose, it is likely to relapse 373 epilepsy. FDA guidelines for remedial administration of antiepileptic drugs are vague. 374 Therefore, PPK models plus TDM can be used to give more precise and quantitative 375 remedy for patients with missed dose. It can minimize the deviation time from the 376 treatment window and maximize the benefit of patients.

## 377 Acknowledgments:

378	The authors would like to sincerely thank Dr. Vincent Jullien from Service de
379	Pharmacologie, Hôpital européen Georges Pompidou, France; Yang Wang and Jing
380	Peng from Department of Pharmacy, Wuhan Children's Hospital, China; Yunli Yu
381	from Department of Clinical Pharmacology, The Second Affiliated Hospital of
382	Soochow University, China for providing details about the research and active
383	discussions on the coding. We would like to thank Hai-ni Wen MPharm from
384	Shanghai Chest Hospital; and Ph.D. candidate Xiao-qin Liu from Department of
385	Pharmacy, Huashan Hospital, Fudan University, China for their critical comments.
386	We would also like to thank Editage (www.editage.cn) for English language editing.
387	Funding: Not applicable.
388	Declaration of interest

Yue-ting Chen, Chen-yu Wang, Yi-wei Yin, Zi-ran Li, Wei-wei Lin, Min Zhu andZheng Jiao declare that they have no conflict of interest.

#### **391** Author contributions

Yue-ting Chen: Data curation, Writing- Original draft preparation, WritingReviewing and Editing, Visualization; Chen-yu Wang: Data curation, WritingReviewing and Editing; Yi-Wei Yin: Writing- Reviewing and Editing, Supervision;
Zi-ran Li: Software, Writing- Reviewing and Editing; Wei-wei Lin: Software,
Validation, Writing- Reviewing and Editing; Min Zhu: Software; Zheng Jiao:
Conceptualization, Methodology, Writing- Reviewing and Editing, Supervision.

## 398 Reference

- Schwabe S. Oxcarbazepine: clinical development program. Epilepsia. 1994;35
   Suppl 5:S51-3.
- Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the
  management of epilepsy. CNS Drugs. 2001;15(2):137-63.
- 403 3. Schachter SC. Oxcarbazepine: current status and clinical applications. Expert
  404 Opin Investig Drugs. 1999 Jul;8(7):1103-12.
- 405 4. Maiti R, Mishra BR, Sanyal S, et al. Effect of carbamazepine and
  406 oxcarbazepine on serum neuron-specific enolase in focal seizures: A
  407 randomized controlled trial. Epilepsy Res. 2017 Dec;138:5-10.
- 408 5. Schütz H, Feldmann KF, Faigle JW, et al. The metabolism of
  409 14C-oxcarbazepine in man. Xenobiotica. 1986 Aug;16(8):769-78.
- 410 6. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of
  411 oxcarbazepine. Clin Pharmacokinet. 2003;42(12):1023-42.
- 412 7. Di Girolamo G, Opezzo JA, Schere D, et al. Parent drug and/or metabolite?
- 413 Which of them is most appropriate to establish bioequivalence of two oral
- 414 oxcarbazepine formulations in healthy volunteers? Expert Opin Pharmacother.
- 415 2007 Jul;8(10):1415-23.
- Lu Y, Fang Y, Wu X, et al. Effects of UGT1A9 genetic polymorphisms on
  monohydroxylated derivative of oxcarbazepine concentrations and
  oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy. Eur
- 419 J Clin Pharmacol. 2017 Mar;73(3):307-315.

- 420 9. van Heiningen PN, Eve MD, Oosterhuis B, et al. The influence of age on the
- 421 pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol
  422 Ther. 1991 Oct;50(4):410-9.
- Patsalos PN, Elyas AA, Zakrzewska JM. Protein binding of oxcarbazepine and
  its primary active metabolite, 10-hydroxycarbazepine, in patients with
- trigeminal neuralgia. Eur J Clin Pharmacol. 1990;39(4):413-5.
- 426 11. Flesch G. Overview of the clinical pharmacokinetics of oxcarbazepine. Clin
  427 Drug Investig. 2004;24(4):185-203.
- Rouan MC, Lecaillon JB, Godbillon J, et al. The effect of renal impairment on
  the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin
  Pharmacol. 1994;47(2):161-7.
- 431 13. Sachdeo R, Beydoun A, Schachter S, et al. Oxcarbazepine (Trileptal) as
  432 monotherapy in patients with partial seizures. Neurology. 2001 Sep
  433 11;57(5):864-71.
- 434 14. Bring P, Ensom MH. Does oxcarbazepine warrant therapeutic drug monitoring?
  435 A critical review. Clin Pharmacokinet. 2008;47(12):767-78.
- 436 15. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual
  437 pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972
  438 Oct;5(5):411-59.
- 439 16. Sasaki T, Tabuchi H, Higuchi S, et al. Warfarin-dosing algorithm based on a
  440 population pharmacokinetic/pharmacodynamic model combined with
  441 Bayesian forecasting. Pharmacogenomics. 2009 Aug;10(8):1257-66.

442	17.	Kanji S, Hayes M, Ling A, et al. Reporting Guidelines for Clinical
443		Pharmacokinetic Studies: The ClinPK Statement. Clin Pharmacokinet. 2015
444		Jul;54(7):783-95.

- 445 18. Jamsen KM, McLeay SC, Barras MA, et al. Reporting a population
  446 pharmacokinetic-pharmacodynamic study: a journal's perspective. Clin
  447 Pharmacokinet. 2014 Feb;53(2):111-22.
- 448 19. Burns DR, Elswick RK, Jr. Equivalence testing with dental clinical trials. J
  449 Dent Res. 2001 Jun;80(6):1513-7.
- 450 20. Ahmad A, Garnett WR. Carbamazepine extended-release capsules vs.
  451 oxcarbazepine: computer simulations of the effect of missed doses on drug
  452 plasma concentrations. Curr Med Res Opin. 2005 Sep;21(9):1363-8.
- Ling J, Qian LX, Ding JJ, et al. [Effects of multiple-trough sampling design
  and algorithm on the estimation of population and individual pharmacokinetic
  parameters]. Yao Xue Xue Bao. 2014 May;49(5):686-94.
- Liu M, Ma CL, Jiao Z, et al. Population pharmacokinetics of oxcarbazepine in
  Chinese epilepsy patients [Article]. Yaoxue Xuebao. 2018;53(8):1318-1323.
- 458 23. Sallas WM, Milosavljev S, D'Souza J, et al. Pharmacokinetic drug interactions
  459 in children taking oxcarbazepine. Clin Pharmacol Ther. 2003
  460 Aug;74(2):138-49.
- 461 24. Sugiyama I, Bouillon T, Yamaguchi M, et al. Population pharmacokinetic
  462 analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric
  463 epileptic patients shows no difference between Japanese and other ethnicities.

464 Drug Metab Pharmacokinet. 2015 Apr;30(2):160-7.

- 465 25. Northam RS, Hernandez AW, Litzinger MJ, et al. Oxcarbazepine in infants
  466 and young children with partial seizures. Pediatr Neurol. 2005
  467 Nov;33(5):337-44.
- 468 26. Park KJ, Kim JR, Joo EY, et al. Drug interaction and pharmacokinetic
  469 modeling of oxcarbazepine in korean patients with epilepsy. Clin
  470 Neuropharmacol. 2012 Jan-Feb;35(1):40-4.
- 471 27. Peng J, Zhang HN, Liu ZS, et al. Population pharmacokinetics of
  472 oxcarbazepine active metabolite in Chinese children with epilepsy. Int J Clin
  473 Pharmacol Ther. 2014 Aug;52(8):684-92.
- Wang Y, Zhang HN, Niu CH, et al. Population pharmacokinetics modeling of
  oxcarbazepine to characterize drug interactions in Chinese children with
  epilepsy. Acta Pharmacol Sin. 2014 Oct;35(10):1342-50.
- 477 29. Lin WW, Wang CL, Jiao Z, et al. Glomerular Filtration Rate Is a Major
- 478 Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese
- 479 Epileptic Patients: A Population Pharmacokinetic Analysis. Ther Drug Monit.
  480 2019 Oct;41(5):665-673.
- 481 30. Lin WW, Li XW, Jiao Z, et al. Population pharmacokinetics of oxcarbazepine 482 active metabolite in Chinese paediatric epilepsy patients and its application in Pharmacol. 483 J Clin 2019 individualised dosage regimens. Eur 484 Mar;75(3):381-392.
- 485 31. Chen CY, Zhou Y, Cui YM, et al. Population pharmacokinetics and dose

- 486 simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. J
- 487 Clin Pharm Ther. 2019 Apr;44(2):300-311.
- 488 32. Rodrigues C, Chiron C, Rey E, et al. Population pharmacokinetics of
  489 oxcarbazepine and its monohydroxy derivative in epileptic children. Br J Clin
  490 Pharmacol. 2017 Dec;83(12):2695-2708.
- 491 33. Yu Y, Zhang Q, Xu W, et al. Population pharmacokinetic modeling of
  492 oxcarbazepine active metabolite in Chinese patients with epilepsy. Eur J Drug
  493 Metab Pharmacokinet. 2016 Aug;41(4):345-51.
- 494 34. Antunes NJ, van Dijkman SC, Lanchote VL, et al. Population
  495 pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine
  496 in healthy subjects. Eur J Pharm Sci. 2017 Nov 15;109s:S116-s123.
- Wegner I, Edelbroek P, de Haan GJ, et al. Drug monitoring of lamotrigine and
  oxcarbazepine combination during pregnancy. Epilepsia. 2010
  Dec;51(12):2500-2.
- 500 36. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution
  501 errors to evaluate nonlinear mixed-effect models: the npde add-on package for
  502 R. Comput Methods Programs Biomed. 2008 May;90(2):154-66.
- Ahn JE, Birnbaum AK, Brundage RC. Inherent correlation between dose and
  clearance in therapeutic drug monitoring settings: possible misinterpretation in
  population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn. 2005
  Dec;32(5-6):703-18.
- 507 38. Perucca E. Pharmacokinetic variability of new antiepileptic drugs at different

508	ages. The	er Drug Moni	t. 2005 Dec;	27(6):714-7.

- 509 39. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at
- the extremes of age. Clin Pharmacokinet. 2006;45(4):351-63.
- 511 40. Choonara IA, McKay P, Hain R, et al. Morphine metabolism in children. Br J
  512 Clin Pharmacol. 1989 Nov;28(5):599-604.
- 41. de Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans.
  Pharmacogenetic and developmental aspects. Clin Pharmacokinet. 1999
  Jun;36(6):439-52.
- 42. Piña-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive therapy
  in infants and young children with partial seizures. Neurology. 2005 Nov
  8;65(9):1370-5.
- McKee PJ, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled
  interaction study between oxcarbazepine and carbamazepine, sodium
  valproate and phenytoin in epileptic patients. Br J Clin Pharmacol. 1994
  Jan;37(1):27-32.
- 44. French JA, Baroldi P, Brittain ST, et al. Efficacy and safety of
  extended-release oxcarbazepine (Oxtellar XR<sup>TM</sup>) as adjunctive therapy in
  patients with refractory partial-onset seizures: a randomized controlled trial.
  Acta Neurol Scand. 2014 Mar;129(3):143-53.
- 527 45. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice 528 guidelines for therapeutic drug monitoring: a position paper by the 529 subcommission on therapeutic drug monitoring, ILAE Commission on

530 Therapeutic Strategies. Epilepsia. 2008 Jul;49(7):1239-76.

531

532 Figure legends

533 Fig. 1 PRISMA flow diagram for the identification of population 534 pharmacokinetic studies.

535

# 536 Fig. 2 Concentration-time profiles at steady state for (a) infants, (b) children, and

537 (c) adults in retrieved studies.

The solid line represents median of the simulated concentration-time profile. The light shadows represent the 10th-90th percentiles of the simulated concentration-time profiles. The estimated glomerular filtration rate (eGFR) was set to 90 mL/min for adults. The alanine aminotransferase (ALT) for children was set to 30 U/L. Age was set to 18-75 years. All patients were assumed to be male receiving OXC monotherapy at a dose of 300 mg for infants and children; 600 mg for adults.

544

#### 545 Fig. 3 Investigated and identified covariates for clearance of oxcarbazepine.


AST: aspartate aminotransferase; ALT: alanine aminotransferase; BSA: body surface
area; BMI: body mass index; BUN: blood urea nitrogen; SCr: serum creatinine; eGFR:
the estimated glomerular filtration rate; HCT: red blood cell specific volume; HGB:
hemoglobin; HT: height; LTG: lamotrigine; LEV: levetiracetam; VPA:
co-administration with valproate acid; WT: weight.


551


#### 552 Fig. 4 Covariate effect on the clearance of oxcarbazepine.

The horizontal bars represent the covariate effect on clearance in each study. The typical value of clearance in each study was considered to be 1. The effect of each covariate for clearance is displayed by the ratio of clearance in the range of each covariate to the typical clearance value. The shaded gray area ranges from 0.8 to 1.25. ALT: alanine aminotransferase; eGFR: the estimated glomerular filtration rate; LEV: levetiracetam; LTG: lamotrigine; VPA: co-administration with valproate acid; Y: yes, co-administration; N: no, not co-administration; M: male; F: female.


560








Peng et al.(2014) Wegner et al.(2013) Wegner et al.(2013) Peng et al.(2014) Wang et al.(2014) Sugiyama et al. (2015) Rodrigues et al.(2017) Chen et al. (2019) Lin et al.(2019) Park et al.(2012) Lin et al.(2019) Antunes et al.(2017) Sugiyama et al. (2015) Northam et al.(2005) Sugiyama et al. (2015) Northam et al.(2005) Sugiyama et al. (2015) Northam et al.(2005) Park et al.(2012) Wang et al.(2014) Rodrigues et al.(2017) Wang et al.(2014) Wang et al.(2014) Peng et al.(2014) Lin et al.(2019) Yu et al.(2016)





Authors and Items	Northam	Park	Wegner	Peng	Wang	Sugiyama	Yu	Antunes	Rodrigues	Chen	Lin	Lin	Compliance
	et al. (2005)	et al. (2012)	et al. (2013)	et al. (2014)	et al. (2014)	et al. (2015)	et al. (2016)	et al. (2017)	et al. (2017)	et al. (2019)	et al. (2019)	et al. (2019)	rate (%)
Title/abstract													
drug and patient population	+	+	+	+	+	+	+	+	+	+	+	+	100
name of the drug(s) studied	+	+	+	+	+	+	+	+	+	+	+	+	100
route of administration	+	+	+	+	+	+	+	+	+	•	+	+	91.7
population studied	+	+	+	+	+	+	+	+	+	+	+	+	100
primary objective	+	+	+	+	+	+	+	+	+	+	+	+	100
major findings	+	+	+	+	+	+	+	+	+	+	+	+	100
Background													
pharmacokinetic data	+	+	+	+	+	+	+	+	+	+	+	+	100
study rationale	+	+	+	+	+	+	+	+	+	+	+	+	100
specific objectives/hypotheses	+	+	+	+	+	+	+	+	+	+	+	+	100
Methods													
eligibility criteria	+	•	+	+	+	+	+	+	+	+	+	+	91.7
co-administration or food	+	+	+	+	+	+	•	+	+	+	+	+	91.7
dosing	•	+	-	+	+	+	+	+	+	+	+	+	83.3
formulation	-	+	+	+	+	+	+	+	+	+	+	+	91.7
sampling schedule	-	•	-	•	+	•	+	•	+	-	-	-	25
bioanalytical methods	+	+	-	+	+	+	+	-	+	+	+	+	83.3

Table 1 ClinPK checklist of information to be included when reporting a clinical pharmacokinetic study.

Table1. (Continued)	NT (1	<b>.</b> .	***	<b>D</b>	***	a .	<b>X</b> 7	• •	<b>D</b> 11	<u></u>			a
Authors and Items	Northam et al. (2005)	Park et al. (2012)	Wegner et al. (2013)	Peng et al. (2014)	Wang et al. (2014)	Sugiyama et al. (2015)	Yu et al. (2016)	Antunes et al. (2017)	Rodrigues et al. (2017)	Chen et al. (2019)	Lin et al. (2019)	Lin et al. (2019)	Compliance rate (%)
methods for handling missing	•	•	•	•	•	•	•	•	•	•	•	•	0
data													
modeling software	+	+	+	+	+	+	+	+	+	+	+	+	100
statistical methods and software	-	+	•	•	+	+	•	-	+	+	+	+	58.3
candidate structural models	•	•	•	+	+	+	+	+	+	+	+	+	75
residual error structure	+	+	+	•	+	+	•	+	+	+	+	+	83.3
methods for base model	•	•	•	+	+	+	+	+	+	+	+	+	75
determination													
methods for base model				+	+	+	+	+	+	+	+	+	75
evaluation													
covariates analysis strategy	-	•	+	+	+	+	•	+	+	-	+	+	66.7
methods for final model	+	+	+	+	+	+	+	+	+	+	+	+	100
evaluation													
distribution of individual model	+	+	+	+	+	+	+	+	+	+	+	+	100
parameters													
estimation method(s) used	+	+	+	+	+	+	+	+	+	+	+	+	100
Results													
population characteristic	+	+	+	+	+	+	+	+	+	+	+	+	100

Table1. (Continued)           Authors and Items	Northam	Park	Wegner	Peng	Wang	Sugiyama	Yu	Antunes	Rodrigues	Chen	Lin	Lin	Compliance
	et al. (2005)	et al. (2012)	et al. (2013)	et al. (2014)	et al. (2014)	et al. (2015)	et al. (2016)	et al.	et al. (2017)	et al. (2019)	et al. (2019)	et al. (2019)	rate
	(2005)	(2012)	(2013)	(2014)	(2014)	(2015)	(2010)	(2017)	(2017)	(2019)	(2019)	(2019)	(%)
schematic of the final model	+	•	+	+	+	+	+	+	+	+	+	+	91.7
No. of subjects and observations	+	+	-	+	+	+	+	+	+	+	+	+	91.7
table of the final model	-	+	+	+	+	+	+	+	+	+	+	+	91.7
parameters													
final model evaluation plots	+	+	+	+	+	+	+	+	+	+	+	+	100
summary of the model-building	+	-	+	+	+	+	+	+	+	+	+	+	91.7
process and the derived final													
model													
plot of concentrations vs. time	+	+	•	+	+	+	+	+	+	+	+	+	91.7
and/or effects vs. concentrations													
Discussion/conclusion													
study limitations	+	•	-	+	+	-	+	+	-	+	+	+	66.7
study findings	+	+	+	+	+	+	+	+	+	+	+	+	100
Compliance rate (%)	71.4	71.4	68.6	88.6	97.1	91.4	85.7	88.6	94.3	88.6	94.3	94.3	/

•: Meet report requirements (record 1 score); •: Not reported (record zero score);

Study (publication year)	Country (type of study)	Number of subjects (Male/Female)	Number of observations	Sampling time	Age(years) Mean ± SD Median [Range]	Weight (kg) Mean ± SD Median [Range]	Formulation	Daily Dose Mean ± SD Median [Range]	Bioassay [LOQ]
Northam et al. (2005)	United States (Prospective)	24 (14/10)	82	$SS^b$	1.7±1.15 [0.2-3.75]	11.3 ± 3.7 [4.7 - 21.8]	NR	Part I <sup>i</sup> : 44.8 [5.3 – 63.2] mg/kg/d Part I <sup>j</sup> : 46.4 [5.3 – 60.9] mg/kg/d.	HPLC/LC-MS NR
Wegner et al. (2013)	Netherlands (Retrospective)	319/464	NR	NR	NR	NR	tablets	NR	HPLC [0.1 mg/L]
Park et al. (2012)	Korea (Retrospective)	209 (97/112)	254	NR	29.0 [3-80]	62.8 [10.1 - 95.0]	tablets	$[945.19 \pm 469.84]$ mg/d	HPLC NR
Wang et al. (2014)	China (Retrospective)	573 (365/208)	1031	NR	7.37±3.6 [0.2-18]	27.64 ± 12.93 [4 - 90]	tablets	[10-30] mg/kg/d	HPLC [0.4 mg/L]
Peng et al. (2014)	China (Retrospective)	466 (300 /166)	840	SS <sup>c</sup>	7.39 [0.58 - 17]	$27.5\pm6.5$	tablets	[75 -1350] mg/d	HPLC NR
Sugiyama et al. (2015)	multicenter <sup>a</sup>	109 (58/51)	376	$SS^d$	11.0±3.9 11 [3-17]	$43.3 \pm 20.7$ [15.9 ± 134.5]	tablets	[300 – 2100] mg/d	HPLC [0.393 mmol/L]
()	Japan (Retrospective)	27	88	SS <sup>e</sup>	10.33±2.63 [5-14]	$34.46 \pm 12.44$ [15.3 - 67.5]	tablets	[312 – 1800] mg/d	LC-MS/MS [0.1 mmol/L]
Yu et al. (2016)	China (Retrospective)	78 (54/24)	108	$SS^{f}$	37±21 [4-81]	NR	tablets	[300 – 1350] mg/d	HPLC [0.4 mg/L]
Antunes et al. (2017)	Brazil (Prospective)	12 (4/8)	185	IS <sup>g</sup>	29.50 [22.00-41.00]	61.75 [48.70 -95.15]	tablets	600 mg/d	LC-MS/MS [OXC: 0.04 mg/L MHD:0.02 mg/L]
Rodrigues et al. (2017)	France (Prospective)	31 (18/13)	556	IS <sup>h</sup>	8.08 [2.25 - 12.5]	23 [12.7 - 56]	tablets or suspension	5 or 15 mg/kg/d	HPLC [OXC: 0.05 mg/L MHD: 0.1mg/L]
Chen et al. (2019)	China (Retrospective)	88 (38/50)	91	NR	4.00 [0.17 ] 15.00]	18.50 [5.25 - 66.30]	suspension	26.09 [7.5 - 54.0] mg/kg/d	HPLC [2mg/L]
Lin et al. (2019)	China (Prospective)	141 (90/51)	301	$C_{trough}$	$7.97 \pm 3.36$ [0.50~14.00]	29.71 ± 12.98 [5.9 - 72.3]	tablets or suspension	618.58 ± 208.23 [120 - 1200] mg/d	EMIT [1.0 mg/L]

Table 2. Characteristics of included population pharmacokinetic studies.

Table 2. (Continue	ed)								
Study (publication year)	Country (type of study)	Number of subjects (Male/Female)	Number of observations	Sampling time	Age(years) Mean ± SD Median [Range]	Weight (kg) Mean ± SD Median [Range]	Formulation	Daily Dose Mean ± SD Median [Range]	Bioassay [LOQ]
Lin et al. (2019)	China (Prospective)	187 (131/56)	316	$C_{\text{trough}}$	37.1 ± 16.1 [18.0 - 90.0]	$62.0 \pm 10.8$ [37.0 - 95.5]	tablets	759 ± 244 [450 - 2700] mg/d	EMIT [1.0 mg/L]

Ctrough: trough concentration; EMIT: enzyme multiplied immunoassay technique; HPLC: high-performance liquid; IS: Intensive sampling; LC-MS/MS: liquid chromatograph mass spectrometer

or mass spectrometer; LOQ: lower limits of quantification; MHD: monohydroxycarbazepine; NR: not reported; OXC: oxcarbazepine; SS: sparse sampling.

<sup>a</sup>multicenter: Argentina, Chile, Uruguay, Australia, New Zealand, Canada, Israel, and the United States.

<sup>b</sup>SS: 0 (pre-dose), 0.5, 2, 5-8 h post-dose.

<sup>c</sup>SS: 0.5-48 h after dose;

<sup>d</sup>SS: at least 1 sample in each of the following intervals: 8 to 11 AM, 11:01 AM to 2 PM, and 2:01 to 6 PM.

<sup>e</sup>SS: Sample 1: trough (about 12 h after the last dose), Sample 2: approximately Tmax (about 4-6 h after administration), Sample 3: initial (around 30 min to 2 h after administration), Sample 4:

trough (at another visit than that for the trough sample 1).

 $^{\rm f}SS:$  0.5–8 h of the dosing interval and  $C_{\rm trough}.$ 

<sup>g</sup>IS: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10 and 12 h post dose.

<sup>h</sup>IS: Part I:1, 2,4, 6, 8, 12, 24, 36, and 48 hours post dose.

<sup>i</sup>Part I: treatment phase.

<sup>j</sup>Part II: extension phases.

Study (publication year)	Software / Algorithm	Fixed eff	ect parameters	Between-su bject variability (%)	residual unexplained variability	Internal validation	External validation (N=number of subjects)	Model application
Northam et al.	NONMEM	Ka	0.598	4.9	3.79 mg/L	GOF	NR	NR
(2005)	/ FO	CL	2.18 × (BSA/1.3) <sup>1.1</sup> × 1.27 (if co-CBZ) × 1.27 (if co-PB) × 1.63 (if co-PHT)	1.8	0.2%			
		V	$50.5 \times (\text{HT}/145)^{-1.96}$	/				
Park et al.	NONMEM	$K_{\rm a}$	0.598	/	23.9%	GOF	NR	NR
(2012)	/ FOCE-I	CL	$2.13 \times (WT/62.8)^{0.666} \times 0.312$ (if co-EIAEDs)	27.7	2.83 mg/L			
		V	49	/				
Wegner et al.	NONMEM	Ka	1	29	9%	Bootstrap	NR	NR
(2013)	/ FOCE-I	CL	$4.66 \times (WT/70)^{0.362} \times (Age/32.8)^{-0.532}$	/	3.8 mg/L			
		V	80	/				
Wang et al.	Phoenix NLME	Ka	0.83	39.82	0.93 mg/L	Bootstrap,	N=115	NR
(2014)	/ FOCE L-B	CL	$0.035 \times WT \times 1.11$ (if co-new-AEDs) $\times 0.97$ (if co-VPA) $\times 1.17$ (if co-EIAEDs)	6.89		GOF		
		V	0.67×WT	19.41				
Peng et al.	Phoenix NLME	Ka	0.6454	/	NR	GOF,	NR	NR
(2014)	/ FOCE	CL	0.5570 + (Dose/WT – 20.8) × 0.003673 - 0.06365 (if female)	12.0		VPC, bootstrap,		
		V	$11.33 + (Age - 7.5) \times 0.02818 + (WT - 25) \times 0.4022$	6.9				
Sugiyama et al.	NONMEM	Ka	0.406	/	18.3%	VPC,	NR	NR
(2015)	/ FOCE	CL	$2.31 \times (WT/41.57)^{0.555} \times 1.33$ (if co-CBZ)	18.0		GOF		
		V	$\times$ 1.34 (if co-PB) $\times$ 1.25 (if co-PHT)	46.6				
			$102 \times (WT/41.57)^{1.70}$	COR: 36.6				
Yu et al.	Phoenix NLME	Ka	0.0833	8.3	NR	Bootstrap,	N=9	NR
(2016)	/ FOCE ELS	Tlag	$0.0904 \times \text{Age}^{(-0.144)}$	157.8		GOF		
		CL	$2.38 \times (ALT/30)^{0.181} \times 1.083$ (if female)	22.4				
		V	$14.2 \times (BUN/4.76)^{(-0.007)} \times (HGB/140)^{(-0.001)}$	104.4				
Antunes et al.	NONMEM	$CL_{MHD}$	$2.01 \times (WT/68)^{0.75}$	9.7	OXC: 9.7%	VPC,	NR	NR
(2017)	/ FOCE	$V_{MHD-R}$	23.6× (WT/68)	1.7	MHD: 1.7%	NPDE,		
		V <sub>MHD-S</sub>	31.7× (WT/68)	/		GOF, PPC		

Table 3. Model strategies and final pharmacokinetic parameters of included studies.

Table 3. (Continued)								
Study (publication year)	Software / Algorithm	Fixed eff	ect parameters	Between-su bject variability (%)	residual unexplained variability	Internal validation	External validation (N=number of samples)	Model application
Rodrigues et al.	Monolix	$K_{\mathrm{a}}$	1.83	/	OXC: 32%	VPC,	NR	design dosing
(2017)	/ SAEM	CLOXC	$140 \times (WT/70)^{0.798}$	39.3	MHD:	NPDE,		regime
		Vc, <sub>OXC</sub>	$337 \times (WT/70)^{2.4}$	60.1	0.993mg/L	GOF		
		Qoxc	62.5	91.9	4.0%			
		Vp, <sub>OXC</sub>	60.7	126				
		CL <sub>MHD</sub>	$4.11 \times (WT/70)^{0.549} \times 0.77$ (if co-EIAEDs)	23.5				
		Vc, <sub>MHD</sub>	$54.8 \times (WT/70)^{-1.09}$	21.1				
		KBT	0.0622	63				
Chen et al.	NONMEM	$K_{\mathrm{a}}$	0.598	/	5.12mg/L	Bootstrap,	N=10	design dosing
(2019)	/ FOCE-I	CL	$3.25 \times (WT/70)^{0.75}$	34.2		GOF,		regime
		V	151.41 × (WT/70)	/		NPDE, VPC		
Lin et al.	NONMEM	Ka	0.83	11.1	2.992mg/L	GOF,	NR	design dosing
(2019)	/ FOCE-I	CL	$1.68 \times (WT/70)^{0.624 \cdot 0.233 \times WT^{219}/(8.97^{219} + WT^{219})}$	/		bootstrap		regime
		V	14.7	/				
Lin et al.	NONMEM	Ka	0.46	/	24.5%	GOF,	NR	design dosing
(2019)	/ FOCE-I	CL	$2 \times (WT/70)^{0.46} \times (eGFR/80)^{0.741}$	12.7		Bootstrap,		regime
		V	102	58.7		NPDE		-

ALT: alanine aminotransferase (U/L); BUN: blood urea nitrogen (mmol/L); BSA: body surface area (m<sup>2</sup>); CBZ: carbamazepine; CL: apparent clearance (L/h); CL<sub>OXC</sub>: the apparent elimination clearances of OXC (L/h); COR: covariance between CL and V; co-X: co-administration with medications; eGFR: the estimated glomerular filtration rate (ml/min); EIAEDs: Enzyme-inducing antiepileptic drug; F: bioavailability; FOCE: first order conditional estimation; FOCE-I: first-order conditional estimation with the interaction; FOCE ELS: first-order conditional estimation method with the  $\eta$ - $\varepsilon$  interaction option; FOCE L-B: first-order conditional estimation method with the  $\eta$ - $\varepsilon$  interaction option; GOF: goodness-of-fit plot; Ka: absorption rate constant (h<sup>-1</sup>); HGB: hemoglobin (g/L); HT: height (cm); KBT: the back-transformation constant rate of MHD into OXC (h<sup>-1</sup>); NR: not reported; new-AEDs: newer antiepileptic drug such as levetiracetam, lamotrigine; NPDE: normalized prediction distribution errors; PB: phenobarbital; PHT: phenytoin; PPC: posterior predictive check; Q<sub>OXC</sub>: the apparent distribution clearances of OXC; SAEM: stochastic approximation expectation maximization; Tlag: absorption lag time (h); Vc, <sub>OXC</sub>: the apparent central distribution volumes of OXC (L); Vd: apparent volume of distribution (L); Vp, <sub>OXC</sub>: the apparent peripheral distribution volumes of OXC (L); VPA: valproic acid; VPC: visual predictive check. WT: Weight (kg);